Targeting the GABAB receptors for the treatment of gastroesophageal reflux disease and chronic cough

Anders Lehmann, L. Ashley Blackshaw, Brendan J. Canning

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations


Transient lower esophageal sphincter relaxation (TLESR) is the dominating motor event behind gastroesophageal reflux (GER) and therefore an important factor in gastroesophageal reflux disease (GERD). TLESR is a reflex dependent on the vagus and as such, it shares many similarities with the cough reflex. Moreover, GER is a known cause of chronic cough in some patients, and agents inhibiting both TLESR and cough may be useful antitussives. There is no effective therapy for GERD patients whose symptoms are not fully resolved by proton pump inhibitor (PPI) therapy and marketed antitussives have poor effects in most patients suffering from chronic cough. The observations that GABA type B (GABAB) receptor agonists reduce TLESR and inhibit cough regardless of stimulus open new inroads to the treatment of PPI-resistant GERD as well as GER-related cough. The present review focuses on these aspects and discusses the findings of GABAB receptor agonists on TLESR, GER, GERD, and cough in both the preclinical setting, healthy individuals and patients. Special attention is devoted to the role of the vagus in mediating these pharmacological effects.

Original languageEnglish (US)
Title of host publicationReceptors
PublisherHumana Press Inc.
Number of pages28
StatePublished - 2016

Publication series

ISSN (Print)1048-6909
ISSN (Electronic)2524-6488


  • Baclofen
  • Chronic cough
  • GABA
  • Gastroesophageal reflux
  • Lesogaberan
  • Transient lower esophageal sphincter relaxation
  • Vagus

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Targeting the GABAB receptors for the treatment of gastroesophageal reflux disease and chronic cough'. Together they form a unique fingerprint.

Cite this